CelLBxHealth plc (LSE:CLBX) has highlighted new independent research showing that circulating tumor cells captured using its Parsortix platform reflected genetic characteristics found in glioblastoma tumor tissue, supporting further investigation of the technology for liquid biopsy applications in brain cancer.
The peer-reviewed study, published in JCO Precision Oncology, analysed Parsortix-enriched circulating tumor cells, or CTCs, from patients with glioblastoma. Researchers found that mutations and chromosomal alterations detected in the captured cells corresponded with changes identified in tumor tissue.
The study also proposed a numerical CTC threshold for distinguishing patients with glioblastoma from healthy controls. Combined with CelLBxHealth’s own data in glioblastoma, the findings provide further evidence for evaluating Parsortix-based CTC analysis as a complementary approach to diagnosis and disease monitoring.
The potential application is particularly relevant in glioblastoma because obtaining repeat tissue biopsies can carry significant risks, while conventional imaging may be difficult to interpret in some circumstances. A blood-based approach capable of providing molecular information could therefore offer a less invasive way of generating additional information about a patient’s disease.
Parsortix is designed to capture CTCs from blood while preserving them for subsequent molecular analysis. The cells can then be assessed using established laboratory techniques covering areas such as imaging, genomic analysis and protein profiling.
While the study strengthens the research case for Parsortix in glioblastoma, further clinical development would be needed to establish how the approach could ultimately be incorporated into diagnosis or patient monitoring.
CelLBxHealth’s wider outlook remains constrained by significant financial challenges and weak technical indicators. Recent corporate developments provide some positive momentum, but financial performance and valuation considerations continue to weigh on the overall picture.
More about CelLBxHealth plc
CelLBxHealth plc is a circulating tumor cell technology company developing solutions for oncology research, drug development and clinical applications.
Its patent-protected Parsortix platform captures circulating tumor cells from blood for subsequent molecular analysis using standard laboratory technologies, including imaging, proteomic profiling and genomic testing.
The company is pursuing revenue through three principal areas: sales of Parsortix instruments and consumables through CRO and clinical laboratory relationships, clinical trial support and assay development from its GCLP-compliant UK facility, and lab-developed tests advanced internally and through strategic collaborations.
This model gives CelLBxHealth exposure to liquid biopsy and precision oncology applications spanning cancer research, pharmaceutical development and potential clinical testing. Its shares trade on AIM under the symbol CLBX.
Leave a Reply